Drug Delivery Devices Market Size was valued at USD 251.6 Billion in 2022. The Drug Delivery Devices market is projected to grow from USD 263.9 Billion in 2023 to USD 387.0 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.90% during the forecast period (2023 - 2032). Increased use of cutting-edge technology for medicine administration to the target site, as well as rising demand for new drug delivery devices, are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The total market is anticipated to rise as a result of increased adoption of cutting-edge technology for efficiently delivering the medicine to the target site. Moreover, by maximizing the drug's presence at the target site, use of these drug delivery devices lowers the likelihood of side effects. This reduces the dose and its related negative effects. Additionally, by using less of the active pharmaceutical ingredient, this aids in lowering the cost of the final product.
R&D in the field is anticipated to increase in response to the rising need for innovative medication delivery systems. Strategic collaborations between major market players are ongoingly formed to produce cutting-edge technology for diverse applications. AstraZeneca and the biotechnology firm Aptamer Group partnered in January 2019 to explore Aptamer's technology and create a revolutionary kidney drug delivery system. Additionally, the availability of these devices for patients is rising due to the rising acceptance of drug delivery systems in home-care settings.
In response to the rising demand, numerous businesses are creating patient-friendly drug delivery systems, and other market participants are acquiring these businesses to diversify their holdings. Aptar Pharma purchased Noble International and their training drug delivery systems in October 2019. Prefilled syringes and auto-injectors are two examples of the patient-centric enhanced medication delivery training devices Noble International created. Through the use of sophisticated drug delivery systems, this acquisition will assist patients in appropriately administering prescriptions.
Studies are still being conducted to improve the patient-friendliness, accessibility, and accuracy of drug delivery systems. In accordance with this, participants are consistently investigating novel technologies and creating cutting-edge medication delivery systems. In October 2019, Phillips-Medisize, which is now a division of Molex Company, announced that they would introduce a wearable medicine administration system with electronic capabilities. The product is currently in the post-phase three development stage and combines two-day, single-use, disposable technology for subcutaneous medication delivery.
Additionally, the business has previously submitted the New Drug Application (NDA) with important supporting data to the Food and Drug Administration (FDA). This product's debut is anticipated for the second half of 2020. The development of medication delivery systems is also being aided by advancements in polymer science. The creation of such distinctive polymers will improve the precision of the devices' drug delivery. Therefore, it is anticipated that the creation of technologically sophisticated drug delivery systems will fuel market expansion over the course of the projection period. Thus, driving the Drug Delivery Devices market revenue.
The Drug Delivery Devices Market segmentation, based on route of administration, includes oral, ocular, inhalation, nasal, injectable, topical, and others. Oral segment dominated the global market in 2022. There are many different dosage forms available for the oral medication delivery system, including tablets, capsules, syrups, solutions, and suspensions. Films and tablets used for drug delivery are also included in this class. In terms of security, simplicity, cost, and medication stability, oral administration is the preferable method.
The Drug Delivery Devices Market segmentation, based on application, includes cardiovascular, diabetes, cancer, infectious diseases, and others. Diabetes segment dominated the global market in 2022. The main cause of this is the rising incidence of diabetes. For instance, the American Diabetes Association (ADA) reports that in 2018, there were 34.2 million Americans with diabetes, of whom 26.8 million had been diagnosed and 7.3 million had not. The adoption of medication delivery devices in the field of diabetes is therefore anticipated to be influenced by the rising number of instances of diabetes that have been diagnosed.
The Drug Delivery Devices Market segmentation, based on end user, includes hospitals, ambulatory services, and home healthcare. Hospitals segment dominated the Drug Delivery Devices Market in 2022. Different medications and drug delivery methods are employed to address the diverse illnesses that hospitalized patients present with. The use of medication delivery devices in hospitals, however, is anticipated to be impacted by hospital-acquired infections, which could slow segment expansion over the projected period.
Figure 1: Drug Delivery Devices Market, by End User, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Drug Delivery Devices Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Drug Delivery Devices Market dominated this market in 2022 (45.80%). This is brought on by the presence of significant players in the area and the expanding use of drug delivery systems. Additionally, rising regional awareness of the benefits of drug delivery devices is anticipated to promote market expansion in the area. Additionally, rising product approval in nations like the US is anticipated to support market expansion.
The U.S. FDA approved Aptar Pharma's nasal medication delivery system in March 2019. Further, the U.S. Drug Delivery Devices market held the largest market share, and the Canada Drug Delivery Devices market was the fastest growing market in the North America region.Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: DRUG DELIVERY DEVICES MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Drug Delivery Devices market accounted for the healthy market share in 2022. The region's top market participants have a ton of chances thanks in part to developed economies and attractive regulatory frameworks. Further, the German Drug Delivery Devices market held the largest market share, and the U.K Drug Delivery Devices market was the fastest growing market in the European region
The Asia Pacific Drug Delivery Devices market is expected to register significant growth from 2023 to 2032. This is due to the area's rapid economic expansion. Additionally, a sizable patient population in nations like Japan, China, and India is encouraging a variety of end users to use medication delivery systems. Additionally, several kinds of drug delivery systems are being used in Japan to deliver particular sorts of medications. Moreover, China’s Drug Delivery Devices market held the largest market share and the Indian Drug Delivery Devices market was the fastest growing market in the Asia-Pacific region.
Drug Delivery Devices Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Drug Delivery Devices market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Drug Delivery Devices industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Drug Delivery Devices industry to benefit clients and increase the market sector. In recent years, the Drug Delivery Devices industry has offered some of the most significant advantages to medicine. Major players in the Drug Delivery Devices market, including Pfizer, Inc., F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd, Novartis AG, Bayer AG, Becton, Dickinson and Company, and Uniqure NV, are attempting to increase market demand by investing in research and development Applications.
Based in Grand Rapids, Michigan, Corium International develops devices and systems for drug delivery. The company's main areas of focus are the development, production, and commercialization of specialty pharmaceutical products with transdermal and transmucosal delivery systems, as well as preclinical and clinical development programs, primarily focusing on the treatment of neurological disorders. This allows customers to obtain products through the simple, secure, and effective delivery of both small and large molecule therapeutics, which has significant clinical and economic benefits. Adlarity was given the go-ahead by the US FDA in March 2022 to treat individuals with mild, moderate, or severe dementia linked to Alzheimer's.
Pharmaceutical research-based corporation Takeda Pharmaceutical Co Ltd (Takeda) focuses on the development, production, marketing, commercialization, import, and export of pharmaceutical products. The business provides goods in the fields of vaccines, plasma-derived medicines, cancer, gastrointestinal, and rare disorders. Japan, Argentina, Brazil, Mexico, the United States, Denmark, Norway, Poland, Russia, Spain, Switzerland, China, India, and Canada are just a few of the countries where Takeda has operations. It markets its goods both directly and through a network of wholesalers, retail chains, and other buying organizations all over the world.
Takeda collaborates with government agencies, big pharma, and small biotech firms. Along with other places, it is present in the Americas, Europe, and Asia. Tokyo, Japan is home to Takeda's headquarters. For use in preventing attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, TAKHZYRO (lanadelumab-flyo) injection in a single-dose prefilled syringe (PFS) gained US FDA clearance in February 2022.
Key Companies in the Drug Delivery Devices market include
Drug Delivery Devices Industry Developments
June 2022:For the first time in India, Gufic Biosciences Ltd. introduced Dual Chamber Bags, a revolutionary drug delivery method, at competitive pricing.
December 2021:With American Biotech, Gerresheimer AG engaged into a significant agreement to create a novel pump that would continuously provide a medicine for the treatment of uncommon disorders.
November 2020:InPen was introduced by Medtronic and connected with live CGM data from Guardian Connect. The tool offers information on insulin dosage combined with real-time glucose measurements.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 251.6 Billion |
| Market Size 2023 | USD 263.9 Billion |
| Market Size 2032 | USD 387.0 Billion |
| Compound Annual Growth Rate (CAGR) | 4.90% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Route of Administration, Application, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Pfizer, Inc., F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd, Novartis AG, Bayer AG, Becton, Dickinson and Company, and Uniqure NV |
| Key Market Opportunities | High growth potential in developing economies |
| Key Market Dynamics | Increasing adoption of advanced technology for effectively delivering the drug on the target site and increasing demand for novel drug delivery devices |
Drug Delivery Devices Market Highlights:
Frequently Asked Questions (FAQ) :
The Drug Delivery Devices Market size was valued at USD 251.6 Billion in 2022.
The global market is projected to grow at a CAGR of 4.90% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Pfizer, Inc., F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd, Novartis AG, Bayer AG, Becton, Dickinson and Company, and Uniqure NV
The Oral Route of Administration dominated the market in 2022.
The Diabetes Application had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
